AstraZeneca (AZN) Price on Solana

AstraZeneca and Daiichi Sankyo's ENHERTU (trastuzumab deruxtecan) achieved the first Phase III success for a HER2-directed treatment in lung cancer, according to results from the DESTINY-Lung04 trial. The study, targeting patients with HER2-mutant advanced non-small cell lung cancer (NSCLC), delivered a median progression-free survival of 14.3 months versus pembrolizumab plus chemotherapy — a 37% reduction in the risk of disease progression. The result marks a meaningful milestone for precision oncology, given that HER2 mutations define a genomically distinct patient subset within the broader lung cancer market.

The DESTINY-Lung04 data adds to a cluster of recent pipeline readouts reinforcing AstraZeneca's oncology strategy, alongside eight-year survival data from TAGRISSO in early-stage EGFR-mutated lung disease. Regulatory submissions and treatment guideline updates are expected to be the next key catalysts for translating the trial outcome into commercial impact.

AstraZeneca's tozorakimab, an anti-IL-33 monoclonal antibody, demonstrated meaningful reductions in COPD exacerbations across two Phase III trials, OBERON and TITANIA. OBERON showed a 30% reduction in moderate-to-severe exacerbations overall (29% among former smokers), while TITANIA delivered a 29% reduction overall (34% among former smokers). Severe exacerbations fell 36% and 33% respectively. The drug works by blocking IL-33 signaling through both the ST2 and RAGE/EGFR pathways, which are implicated in airway remodeling and mucus production — a mechanism that appears to benefit patients across a broad eosinophil range, with efficacy climbing to 43% reduction in those with eosinophil counts at or above 300.

The FDA has granted tozorakimab priority review, with a decision expected in Q1 2027. CEO Pascal Soriot has described it as a potential $5 billion-plus peak-sales asset across indications, with roughly 6 million COPD patients estimated to be eligible for biologic therapy by 2030. Secondary endpoints showed a ~25 cc FEV1 improvement and statistically significant symptom score improvement (E-RS), though the St. George's Respiratory Questionnaire missed significance. A numerical imbalance in major adverse cardiovascular events was noted in trial data and will likely receive close regulatory scrutiny ahead of the FDA decision.

AstraZeneca's cancer drug Etcamah has failed to meet the primary endpoint of progression-free survival in a late-stage trial evaluating it in combination with palbociclib, a CDK4/6 inhibitor, for previously untreated advanced breast cancer patients. The combination produced only a numerical improvement rather than a statistically significant benefit, Reuters reported on September 11. AstraZeneca said full trial data will be shared in due course.

The result is a notable setback coming just one week after the FDA granted Etcamah accelerated approval for use alongside certain CDK4/6 inhibitor cancer medicines. AstraZeneca's U.S.-listed shares fell approximately 3% in aftermarket trading following the announcement.

AstraZeneca's late-stage trial combining Tagrisso with Orpathys — developed in partnership with Hutchmed — met its primary endpoint, significantly extending progression-free survival over Tagrisso monotherapy in first-line treatment of EGFR-mutated advanced non-small cell lung cancer patients with moderate-to-high MET protein expression. The trial also showed encouraging overall-survival trends, though statistical significance on that secondary objective has not been confirmed. The commercially advantageous first-line positioning expands the addressable population for both drugs and broadens Orpathys' commercial opportunity alongside an established oncology asset.

Oncology medicines account for nearly half of AstraZeneca's total revenues, with Tagrisso among its top-selling products, making pipeline extensions of this kind critical to the company's stated target of $80 billion in annual sales by 2030. A positive regulatory outcome and broad market adoption remain contingent on detailed safety data and approval processes, and the eligible patient population is defined by specific MET expression thresholds that limit generalizability across all lung cancer indications.

AstraZeneca's co-developed drug eplontersen (Wainua), partnered with Ionis Pharmaceuticals, has failed its primary endpoint in the CARDIO-TTRansform Phase 3 trial evaluating the therapy in transthyretin amyloid cardiomyopathy (ATTR-CM). The 1,432-patient study showed 381 events in 210 patients on eplontersen versus 392 events in 231 patients on placebo — a difference that did not reach statistical significance. While eplontersen did reduce transthyretin levels as expected, it delivered minimal clinical benefit, particularly for patients already taking stabilizer medications. AZN shares fell approximately 1% on the full data release.

Jefferies characterized the readthrough as "neutral to negative," noting the results put additional pressure on the broader silencer-drug approach as follow-up therapy after stabilizers in heart disease. The bank flagged particular concern for Alnylam's competing TRITON-CM trial of its own TTR-silencing therapy, which now faces heightened investor scrutiny. For AstraZeneca, the setback narrows a potential growth avenue in cardiovascular disease at a time when the company has been actively diversifying its pipeline beyond oncology.

AstraZeneca and Amgen reported positive Phase 3 results for TEZSPIRE in eosinophilic esophagitis, a rare inflammatory condition of the esophagus, with the trial showing clinically meaningful improvements through week 52. The readout adds to AstraZeneca's late-stage pipeline at a time when the stock trades at a notable discount to analyst fair value estimates.

AstraZeneca shares are priced at £121.14, down roughly 11% year-to-date, while analyst fair value estimates sit around £159.11 — implying an undervaluation of approximately 24%. Analysts cite the company's diversified late-stage pipeline, which carries potential for over $10 billion in peak risk-adjusted revenue from new medicines, as support for a bullish outlook. Key risks include further late-stage trial disappointments and potential drug price controls affecting major revenue products.

AstraZeneca has priced a €2.55 billion multi-tranche euro bond offering managed by Barclays, Goldman Sachs International, and Morgan Stanley. The deal spans four maturities: €700 million due March 2030 at a 3.402% coupon, €600 million due 2032 at 3.652%, €500 million due 2035 at 3.923%, and €750 million due September 2038 at 4.169%. The notes are listed on the London Stock Exchange under the FCA's Official List, and proceeds are designated for general corporate purposes rather than any specific project or acquisition.

The issuance reflects AstraZeneca's positioning as an active borrower in European debt markets, which the company has cited as part of a long-term funding strategy supporting an expanding drug pipeline and substantial manufacturing commitments — including significant US investment. The raise comes one day after the company's $1.5 billion acquisition of Zegfrovy's EGFR lung cancer franchise was reported, though AstraZeneca did not formally link the bond proceeds to that deal. With analysts also weighing potential mega-merger scenarios involving Bristol Myers Squibb, the debt issuance underscores the scale of capital AstraZeneca is mobilising across its near-term strategic agenda.

AstraZeneca is acquiring global rights to Zegfrovy (sunvozertinib) from Dizal Pharmaceutical in a deal worth up to $1.5 billion — $600 million upfront plus up to $900 million in development, regulatory, and sales milestones, along with tiered royalties. Zegfrovy is an oral therapy approved in the U.S. and China for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations, a subset of patients who progressed after platinum-based chemotherapy. Phase III WU-KONG28 trial data showed the drug extended median progression-free survival to 10.3 months versus 7.5 months for chemotherapy, and Dizal reported roughly $85 million in Zegfrovy revenue during 2025 — approximately 85% year-over-year growth ahead of the deal's close.

The acquisition slots into AstraZeneca's existing lung cancer lineup — which already includes Tagrisso, Imfinzi, and Enhertu — and advances the company's stated goal of reaching $80 billion in annual revenue by 2030, with oncology posting double-digit growth in the first half of 2026. Analysts note that the EGFR exon 20 insertion population is relatively narrow and that AstraZeneca has not yet disclosed comprehensive global development timelines or long-range revenue projections for Zegfrovy.

AstraZeneca has abandoned a Phase 3 trial of Volrustomig in combination with chemotherapy for late-stage lung cancer after an Independent Data Monitoring Committee determined the drug was unlikely to improve survival rates compared with existing treatments. The setback adds to a difficult stretch for AstraZeneca's pipeline, following its July decision to halt trials for Wainua, a heart disease treatment, which triggered billions in market-cap losses.

Despite the lung cancer discontinuation, AstraZeneca said it will continue evaluating Volrustomig across other tumour types, including cervical cancer, head and neck squamous cell carcinoma, and mesothelioma. The company's shares rose roughly 2% in early trading, partly offset by positive Phase 3 data for its Enhertu treatment in non-small cell lung cancer, providing some pipeline reassurance to investors.

Analysts are raising significant doubts about the reported $400 billion merger between AstraZeneca and Bristol Myers Squibb, with AstraZeneca shares sliding roughly 9% following the initial reports. While the combined entity would create a dominant oncology-focused pharmaceutical giant with substantial potential synergies, analysts warn that the sheer scale of overlapping cancer market share would invite intense antitrust scrutiny, making regulatory approval far from assured.

Beyond the antitrust risk, the deal faces structural headwinds: Bristol Myers Squibb confronts a looming patent cliff on key drugs including Eliquis and Opdivo, while AstraZeneca itself trades at a premium valuation of nearly 16 times forward earnings relative to most peers. With subsequent reports suggesting the deal is unlikely to materialise, some analysts have advised AstraZeneca shareholders to consider selling into any relief rally rather than waiting for an outcome that may never arrive.